InvestorsHub Logo
Followers 43
Posts 2488
Boards Moderated 0
Alias Born 10/19/2015

Re: grich1 post# 183257

Wednesday, 02/27/2019 6:26:12 PM

Wednesday, February 27, 2019 6:26:12 PM

Post# of 462982
Yup. HIV is a good example. We've essentially turned HIV from a death sentence into a disease like diabetes -- it's there but it can be controlled. The social stigma still exists, but it's not -that- big of a deal anymore provided you have access to the right cocktail of medicine.

I think the same is true for AD. It won't be one pill -- it'll be a cocktail of pills. Hopefully 271 is one of them.

The hardest part though won't be approval. I think the FDA is desperate to find a better alternative to Aricept. I think the hard part will be to convince, initially, the insurers to cover Anavex so it's affordable to the masses. In time they'll come around, but I can see them resisting as much as possible until the last possible minute. They'll call it experimental or something and will want to run their own studies and cost-benefit analysis. Depending on how long this process takes, Anavex may only have a short period of time before its patent expires and generics become available that insurers are more apt to cover.

Missling I think knows this, too. Hence, the international focus.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News